Work

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0255-1

Authors: Khanh Do, Giovanna Speranza, Lun-Ching Chang, Eric C. Polley, Rachel Bishop, Weimin Zhu, Jane B. Trepel, Sunmin Lee, Min-Jung Lee, Robert J. Kinders, Larry Phillips, Jerry Collins, John Lyons, Woondong Jeong, Ramya Antony, Alice P. Chen, Len Neckers, James H. Doroshow, Shivaani Kummar

Institutions: National Cancer Institute, National Eye Institute, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. (United States), National Institutes of Health, Center for Cancer Research

Language: English

Topic: Heat shock proteins research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Astex Pharmaceuticals, National Institutes of Health, National Cancer Institute

Awards: G111615301, G1619438925, G386607036, G5888954722, G9000221830, G9000242716, Cancer Center Support Grant

OpenAlex ID: W612504614

FWCI: 1.672

Cites: 14

Cited by: 51

Related to: 10